Running title: Chiral status of withdrawn drugs
Ayfer Bahar1*, Volkan Aydin2*, Caner Vizdiklar1, Ahmet Akici1
Department of Medical Pharmacology, School of Medicine, Marmara University, Istanbul, Turkey
Department of Medical Pharmacology, International School of Medicine, Istanbul Medipol University, Istanbul, Turkey
* The authors equally contributed to this paper.
Correspondence: Prof Ahmet Akici, MD
Department of Medical Pharmacology, Marmara University School of Medicine, Maltepe 34854, Istanbul, Turkey.
Phone: +902165557700; e-mail:aakici@marmara.edu.tr
Ethical approval: This study was approved by Ethics Committee for Non-interventional Clinical Studies of Marmara University Institute of Health Sciences (Approval number: 16.11.2020-91).
Acknowledgements : We thank to Dr. Igho Onakpoya and his co-workers for their tremendous efforts and earlier studies on withdrawn drugs that inspired us to investigate another aspect of the subject.
Competing Interests: The authors declare they have no competing or conflict of interest.
Funding: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Contributions: Conception and design: AB, AA, VA; Acquisition of data: AB, CV, VA; Analysis and interpretation of data: VA, AB, CV; Writing first draft: VA, AB, CV, AA; Critical review and supervision: AA, VA; Final approval to the submitted version of the manuscript: AB, VA, CV, AA.
Data availability: The data that support the findings of this study are available from the corresponding author upon reasonable request.
Keywords: pharmacovigilance, pharmacoepidemiology, drug regulation, stereoisomerism
Word count: 2682, Table count: 4, Figure count: 1